Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference
Fulcrum Therapeutics, Inc. (FULC)
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a virtual fireside chat at the 2022 BofA Securities Biotech SMID Cap Conference, on Thursday, December 8, 2022 at 9:10 a.m. ET A live audio webcast will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. An archived replay will be available on the Company’s website for 30 days. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD)
Show less
Read more
Impact Snapshot
Event Time:
FULC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FULC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FULC alerts
High impacting Fulcrum Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FULC
News
- Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy SymposiumGlobeNewswire
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical OfficerGlobeNewswire
- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $14.00 price target on the stock.MarketBeat
FULC
Earnings
- 2/27/24 - Beat
FULC
Sec Filings
- 4/19/24 - Form ARS
- 4/19/24 - Form DEFA14A
- 4/19/24 - Form DEF
- FULC's page on the SEC website